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Abstract: Aceclofenac-loaded poly(vinyl-pyrrolidone)-based nanofiber formulations were prepared
by electrospinning to obtain drug-loaded orally disintegrating webs to enhance the solubility and
dissolution rate of the poorly soluble anti-inflammatory active that belongs to the BCS Class-II.
Triethanolamine-containing ternary composite of aceclofenac-poly(vinyl-pyrrolidone) nanofibers
were formulated to exert the synergistic effect on the drug-dissolution improvement. The composition
and the electrospinning parameters were changed to select the fibrous sample of optimum fiber
characteristics. To determine the morphology of the nanofibers, scanning electron microscopy was
used. Fourier transform infrared spectroscopy (FT-IR), and differential scanning calorimetry (DSC)
were applied for the solid-state characterization of the samples, while the drug release profile was
followed by the in vitro dissolution test. The nanofibrous formulations had diameters in the range
of few hundred nanometers. FT-IR spectra and DSC thermograms indicated the amorphization
of aceclofenac, which resulted in a rapid release of the active substance. The characteristics of the
selected ternary fiber composition (10 mg/g aceclofenac, 1% w/w triethanolamine, 15% w/w PVPK90)
were found to be suitable for obtaining orally dissolving webs of fast dissolution and potential
oral absorption.
Keywords: aceclofenac; nanofiber; electrospinning; scanning electron microscopy; fourier transform
infrared spectroscopy; differential scanning calorimetry
1. Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are often used in the therapy of osteoarthritis
and rheumatoid arthritis for pain relief and to reduce inflammation. NSAIDs inhibit both isoforms of
cyclooxygenase enzyme (COX), but their analgesic and anti-inflammatory effects are due to inhibition
of COX-2 [1]. The adverse effects such as gastrointestinal bleeding and ulcer, stroke, heart attacks are
primarily caused by the inhibition of COX-1 [2,3]. The risk of side effects increases with high doses and
long duration of systemic exposure to NSAIDs [4].
Aceclofenac is a potent NSAID with significant anti-inflammatory and analgesic properties. Its
effect is achieved by inhibiting the production of inflammatory mediators including prostaglandin E2
(PGE2), tumor necrosis factors (TNF) and different interleukins (IL1-β, IL-2) [5,6]. Aceclofenac also has
chondroprotective effects by the synthesis of glycosaminoglycan [6–8]. It is reported to be more potent or
at least to have similar anti-inflammatory effects than conventional NSAIDs in double-bind studies [9,10].
Aceclofenac has a better gastric tolerance, explained by its higher selectivity towards COX-2 than
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COX-1, which explains its safety compared to traditional NSAIDs and COX-2 selective inhibitors [1,6,8].
The drug is practically insoluble in water, belongs to the Biopharmaceutical Classification System (BCS)
Class II. [6] After oral administration aceclofenac is well absorbed, however, its bioavailability is reduced
due to high first pass metabolism and poor aqueous solubility of the drug [6,8].
There are numerous technological methods to increase the bioavailability of a drug. For BCS class
II drugs, this can be achieved by enhancing the dissolution of the poorly water-soluble active substance
by reducing particle size, preparation of water-soluble complexes, using surfactant systems, liposomes,
and formulation of solid dispersions [11]. Among the different kinds of solid dispersion strategies
new type of solid dispersions, typically ternary or quaternary systems, with one or two additives
(such as surfactants and other polymeric excipients) that, together with the drug and host polymer, are
combined to exert a synergistic effect on drug-dissolution improvement. The polymer-based solid
dispersions are amorphous composites [12].
The oral bioavailability of aceclofenac could be enhanced using chitosan cocrystals trapped into
the alginate matrix as a supersaturated drug delivery system (SDDS) or using polymeric microspheres,
which can act as delivery systems for sustained drug release [13–16]. The production of nanocrystals
using the surface solid dispersion technique is also an appropriate method to improve the dissolution
rate of aceclofenac [17,18]. Triethanolamine was also used to prepare aceclofenac salt to improve
the solubility [19]. In order to minimize the gastrointestinal side effects and to attain controlled
release delivery of the drug, the development of starch-blended Ca2+-Zn2+-alginate microparticles and
aceclofenac-loaded interpenetrating network (IPN) nanocomposites were also described [20,21].
Nowadays nanotechnology is an evolving area for the development of drug delivery systems with
dimensions between 1–100 nm [22]. Nano-carriers have high surface area to volume ratio, can reduce
the side effects of conventional pharmaceuticals and they are successful carriers for insoluble active
ingredients [23]. Core/shell nanoscale particles were prepared with a modified coaxial electrospraying
process in which a very thin shell layer was employed to give very rapid dissolution of a poorly water
soluble helicid [24]. Nanofiber-based drug delivery systems own their high drug uptake due to their
large surface area and porosity, but they are also able to simultaneously deliver more than one drug or
can be used as transdermal drug delivery systems, as well [25].
These nanofibers can be successfully used to prepare orally dissolving webs, an innovative group
of drug delivery systems with several advantages over existing oral formulations such as:
- rapid disintegration and high dissolution rate in the oral cavity due to the large surface area,
- no need of water for administration; this could be an advantage in geriatrics, pediatrics, but also
for dysphagic patients or patients who are unable to swallow tablets and capsules or a large
amount of water,
- precise dosage administration in each film,
- rapid absorption from the highly vascularized buccal mucosa—drugs are absorbed directly to the
superior vena cava, entering into the systemic circulation without pre-systemic metabolism,
- increase in bioavailability and rapid onset of action by avoiding the first-pass hepatic metabolism,
while the dose can be reduced, which can lead to a reduction of side effects [26,27].
The nanofibrous formulations enable sustained drug release, as well. Aceclofenac/pantoprazole
loaded zein/eudragit S 100 nanofibers were developed using a single nozzle electrospinning process
to obtain the sustained release of both the drugs up to 8 h to reduce the gastrointestinal side-effect
of aceclofenac [28]. In contrast to the combined formulation, our concept was to enhance the
bioavailability and reduce the gastrointestinal side effect of aceclofenac with orally dissolving
nanofibrous webs, which can provide fast buccal absorption of active. The present study aimed
to formulate and characterize aceclofenac-loaded nanofiber-based orally dissolving webs from
triethanolamine-containing polyvinylpyrrolidone (PVP) by electrospinning. The morphology, thermal
properties, drug content and drug release profile of the ternary systems were analyzed in order to
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select the right polymer and active substance concentrations concerning the properties of potential
orally dissolving webs.
2. Materials and Methods
2.1. Materials
The active pharmaceutical, aceclofenac (Figure 1a) was provided by Richter Gedeon Plc. (Budapest,
Hungary). For the preparation of the viscous polymeric solutions, poly(vinyl-pyrrolidone) (PVP K90,
Kollidon K90, Figure 1b) was used, which was obtained from Sigma Aldrich (Merck, Darmstadt,
Germany). Triethanolamine (trolamine) and ethanol were from Molar Chemicals (Budapest, Hungary).
Ultrapure, distilled water was prepared in-house by a MilliQ water purification system. Potassium
dihydrogen phosphate and disodium hydrogen phosphate (Merck KGaA, Darmstadt, Germany) were
employed for the preparation of the phosphate buffer solution (1 M, pH 6.8) used for the in vitro
dissolution study.
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Fig re 1. i l tr t res f (a) aceclofe ac and (b) polyvinylpyrrolidone (PVP).
2.2. Methods
2.2.1. Preparation of PVP Solutions Containing Aceclofenac
The active substance was dissolved in a solvent mixture consisting of ethanol and distilled water
in a ratio of 75:25 (w/w), obtaining a final concentration of 10 mg/g. Trolamine and PVP was dissolved
in the obtained solution (amounts described in Table 1) under magnetic stirring until a clear gel was
obtained (700 rpm, 1 h with an Ikamag RET magnetic stirrer).
Table 1. Composition of viscous polymeric solutions used for the preparation of nanofibers, diameters
of the obtained fibers and estimation of the glass transition temperatures.
Sample No. AceclofenacConcentration (mg/g)
PVP Concentration
(w/w%)
Trolamine
Concentration (w/w%)
Diameters
(nm)
Predicted
Tgmix (◦C)
N1 10 13 1 435 ± 159 139.7
N2 10 15 1 596 ± 215 143.6
N3 10 17 1 1046 ± 113 147.1
N4 10 13 3 757 ± 157 89.9
N5 10 15 3 786 ± 322 * 97.9
N6 10 17 3 812 ± 244 * 104.5
* The average diameters were determined from the fibrous elements of the sample, bias.
2.2.2. Electrospinning Process
The resulting gel was transferred into a 1 mL plastic syringe equipped with a metallic needle
( G–0.7 mm in er diamet r). The needle to the collector distance was 10, 12.5 and 15 cm, while the
applied voltage was examined at 14, 15 and 16 kV. For the final formulation, the distance between
the spinneret and the collector was set to 12.5 cm and the applied voltage to 15 kV, the flow rate was
set at 0.1 µL/s. The nanofibers were obtained using the eSpin Cube device (SpinSplit Ltd., Budapest,
Hungary), equipped with an NT-35 high voltage DC supply (Unitronik Ltd., Nagykanizsa, Hungary)
and collected on a vertically-positioned, grounded aluminum plate covered with parchment paper.
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2.2.3. Scanning Electron Microscopic Analysis (SEM)
The morphology of the nanofibers was investigated with a scanning electron microscope (SEM).
The samples were fixed by a double-sided carbon adhesive tape and then coated by a sputtered gold
conductive layer (JEOL JFC-1200 Fine Coater, JEOL Ltd., Tokyo, Japan). SEM images were taken
with a JEOL JSM-6380LA scanning electron microscope (JEOL Ltd., Tokyo, Japan) at 500×, 1500× and
5000× magnifications.
The diameters of the fibers were measured with the aid of the ImageJ software (US National
Institutes of Health, Bethesda, MD, USA) and the average fiber diameter was calculated based on 50
different randomly selected individual filaments at 5000× magnification.
2.2.4. Fourier-Transform Infrared (FT-IR) Spectroscopy
Physicochemical properties of the nanofibers were studied using the Jasco FT/IR-4200
spectrophotometer equipped with the Jasco ATR PRO470-H single reflection accessory (Jasco
Corporation, Tokyo, Japan). The measurements were accomplished in the absorbance mode, and
spectra were collected over a wavenumber range of 4000 and 400 cm−1. 100 scans were performed at a
resolution of 4 cm−1.
2.2.5. Differential Scanning Calorimetry (DSC)
Thermograms of aceclofenac, PVP, physical mixture and nanofibers with and without the drug
were recorded on a Shimadzu DSC-60 type of thermal analyzer (Shimadzu Corporation, Kyoto, Japan).
Samples were accurately weighted in aluminium pans, sealed and scanned from 27 to 250 ◦C under air
atmosphere with a rate of 10 ◦C/min. Al2O3 was used as reference.
2.2.6. Determination of Drug Content of Aceclofenac-Loaded Nanofibers
The absorbance of samples was measured on 277 nm absorption band of aceclofenac using the
Shimadzu UV-1601PC UV spectrophotometer (Shimadzu Corporation, Kyoto, Japan). The stock
solution was prepared by dissolving 10 mg aceclofenac in 10 mL ethanol, then diluting 1 mL to 50 mL
with distilled water, resulting in a final concentration of 20 µg/mL. The drug content was measured
by following the absorbance of the solution prepared by dissolving the nanofibers in the same way.
Samples were assayed from three consecutive electrospinning runs (n = 3).
2.2.7. In Vitro Drug Dissolution Test
Small volume dissolution tests were performed in an in-house assembled dissolution setup, as
described in our earlier publication [29]. In order to demonstrate the small-volume dissolution in the
oral cavity, dissolution tests of aceclofenac-loaded nanofibers were investigated in 20 mL of dissolution
medium, at 37.0± 1 ◦C. As dissolution medium phosphate buffer (pH 6.8, 1 M, Ph. Eur. 8) was prepared.
Aceclofenac samples (around 3 mg) and N2 fiber samples (corresponding to 3 mg aceclofenac, around
50 mg nanofiber, each) were put into six test tubes equipped with a magnetic stirring bar. The stir
rate was set to 200 rpm. The dissolution was followed for 30 min. At predetermined time points
(1 min, 3 min, 5 min, 10 min, 15 min, 30 min), 1 mL samples were withdrawn and filtered through
a 10 µm Whatman filter. 300 µL sample was diluted to 3.0 mL with dissolution media. Aceclofenac
concentration was determined spectrophotometrically at 277 nm.
3. Results and Discussion
3.1. Morphology of the Aceclofenac-Loaded Nanofibers
Morphology of the obtained nanofibers were examined by SEM. Figure 2 represents the SEM images
of samples with 13%, 15% and 17% PVP content with different trolamine proportions, with 12.5 cm
emitter to collector distance.
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Figure 2. SEM morphology of iffere t t 00× magn fication.
When compared to the la ine content, on the images of samples with 3% trolamine,
the deterioration of nanofibers can be observed, which could be the consequence of the plasticization
effect of higher trolamine content. T e l tter is i d agreement with the results of the authors’
previous works [29,30], where the film for ation occurred as a result of the glassy-to-rubbery transition
of the polymeric carriers. The moisture absorbed from the environment acts also as a plasticizer
leading to a significant decrease of the Tg of the fiber-forming polymers. Among the samples with 1%
trolamine content, the fibers with 15% PVP content proved to be the most suitable for their intended
use. The obtained fibers presented diameters from approximately 200 to 800 nanometers with an
average of 596 ± 215 nm, with smooth, uniform surfaces. Thus, the composition N2 was used for
further studies. Along with the increase of the trolamine concentration the nanofiber structure was
shifted to film formation, depending on the polymer-trolamine ratio of the composite fibers. This
phenomenon was visualized on the SEM photos (Figure 2, 3% trolamine-containing samples) and can
be explained by the enhanced molecular mobility of the plasticized fibers and thus the decreased inner
cohesion within the polymeric chains.
3.2. FT-IR Analysis
FT-IR spectra of the components and aceclofenac-loaded nanofibers are represented in Figure 3.
In accordance with earlier reports, the IR spectrum of pure aceclofenac shows characteristic peaks
at around 3318 cm−1 (Figure 3A), which can be attributed to the secondary amine N-H stretching or
carboxylic acid band (O-H stretching), tw ketone bands at around 1714 and 1770 cm−1 and multiple
phenyl ring bands in the finge rint region (Figure 3B) [31]. In the case of the fiber-forming polymer,
PVP presents a strong absorption peak at 1650 cm−1, characteristic for t c rbonyl group (C=O
stretching). The band at 1419 cm−1 is the –CH2 bending vibration, while the band at 1285 cm−1 is
usually assigned to the C-N stretching vibrations [32]. The IR spectrum of trolamine displays a broad
absorption peak at around 3330 cm−1, which correspo ds to O-H stretching, while those at 2817, 2874
and 2947 cm−1, respectively are assigned to fundamental vibrations of the CH bond. IR spectrum of
the nanofibrous sample displays the abovementioned characteristic bonds of both PVP and trolamine,
however, none of the absorption peaks of aceclofenac is clearly distinguishable. The latter could
refer to that the dissolved initially crystalline aceclofenac remained amorphous in the nanofibrous
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formulation. On the other hand, in the region of 1500–500 cm−1 (fingerprint region) the characteristic
peaks of trolamine can be identified (882, 909, 1032 and 1071 cm−1, respectively).
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in ethanol:water 75:25 w/w%).
3.3. DSC Me surements
Figure 4 shows the DSC curves of aceclofenac, PVP, physical mixture, neat fiber and
aceclofenac-loaded nanofiber.
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as in composition N2); (D) PVP and (E) aceclofenac.
The thermogram of aceclofenac presents s t er peak at 154.49 ◦C, indicating its
melting point. The m lting-point depression of aceclofenac (approximately 133.6 ◦C) can be observed
in the physical mixture (see green ins rt) showing the effect of the ads rption of PVP and trol mine
on the surface of aceclofenac and consequently modifying its thermal properties. The small peak
intensity of the aceclofenac melting endotherm refers to its proportion in the physical mixture. On the
curves of aceclofenac-loaded nanofibers, there is a lack of melting endotherm, probably due to the
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amorphization of aceclofenac. Broad endothermic peaks below 100 ◦C on the thermograms of neat,
placebo fibers and aceclofenac-loaded fibers can be associated with the moisture content of the prepared
samples. The increased moisture content of the fibrous samples is associated with their larger surface
area compared to the powder substances; thus, they are prone to absorb more water. Based on
the extent of the peaks, it can be concluded, that the increased hygroscopicity of the fibers, on the
one hand, can have a significant impact on the dissolution improvement of the active, but on the
other hand it could initiate a glassy-to-rubbery transition of the PVP, thus destroying the fibrous
structure. Similar pseudopolymorphism of the fiber-base polymer composite can be seen in the
authors’ previous stability studies of papaverine hydrochloride-loaded electrospun nanofibrous buccal
sheets [30]. The glass transition temperature of PVP K90 denoted by an endothermic change in the
baseline thermal profiles (see blue insert) of reversible heat flow was 179 ◦C [33], which can be more
sensitively detected at 5 ◦C/min heating rate. The presence of solvent residues (e.g., water) and other
excipients, like the solubilizing agent trolamine, decreased the glass transition temperature (indicated
with black arrow) and thus modifying the glassy-to-rubbery transition of the fibrous polymeric carriers.
The estimated glass transition temperature of ternary fibers (Tgmix) calculated based on the Fox equation
(Equation (1), [34]) are as follows
1/Tgmix = (w1/Tg1) +( w2/Tg2) (1)
where w = weight fraction of components, Tg = glass transition temperature of the components.
The predicted glass transition temperature of various fibers, calculated by Equation (1), together
with the average diameters, are summarized in Table 1. The presence of low molecular weight additive,
trolamine lowers the Tg of the ternary composite fibers and consequently increases their free volumes.
The average diameters of the different composite nanofibers (see Table 1) indicated that along with the
increase of the polymer concentration, the obtained fiber diameter also increased at a given plasticizer
content of the initial polymer solution. The increased free volume of the fibers results in enhanced
water absorption, which enables further lowering of the Tgmix and showing rubbery properties at
lower temperatures by creating ribbon-like fibers.
3.4. Determination of Drug Content of Aceclofenac-Loaded Nanofibers
In order to confirm the presence of the active in the prepared nanofibers, comparative UV
spectra were recorded for ethanolic solutions of neat aceclofenac and the nanofibrous web obtained
from composition N2 (Figure 5). The obtained spectra are similar, except the low UV region, where
the solution obtained from the nanofibrous formulation displays a higher absorption due to the
matrix components. For both spectra, λmax values were recorded at 277 nm (i.e., the expected UV
maximum for aceclofenac). Based on the UV spectrometric measurements, the nanofibrous webs
contain 5.77 ± 0.12 w/w% aceclofenac, which corresponds to 98.19 ± 2.04% of the theoretical aceclofenac
content (5.88 w/w%)
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3.5. Dissolution Measurements of the Nanofibers
Figure 6 illustrates the obtained comparative dissolution profiles of the drug-loaded nanofibers
(composition N2 of polymeric solution) and neat aceclofenac. As it can be obse ved, drug release is
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4. Conclusions
This study demonstrated that the nanofiber forming process is influenced by multiple parameters
such as the composition of the aceclofenac-containing viscous solution and the electrospinning
parameters. The SEM studies confirmed the nanofibrous structure, while the FT-IR and DSC tests
can indicate that the originally crystalline aceclofenac was in the amorphous form in the nanofibrous
formulations. Upon exposure to aqueous media, dissolution is believed to generate a supersaturated
state due to the amorphous state of the drug. The dissolution of the polymer matrix was fast
and complete. The selected composition of the triethanolamine-aceclofenac-poly(vinyl-pyrrolidone)
ternary composite resulted in an amorphous drug-loaded electrospun nanofibrous structure of fast
and complete dissolution in aqueous media. Based on the results the formulated aceclofenac-loaded
orally dissolving webs provide a promising alternative in the therapy of osteoarthritis and rheumatoid
arthritis with an enhanced rate and extent of absorption due to the improved wettability and dissolution
rate thus providing smaller effective doses and causing fewer potential side effects.
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